Viral vectors for vascular gene therapy

Experimental and Clinical Cardiology

Volumn 7, Issue 2-3, 2002, Pages 106-112

  Fischer, Lukas ^a   Preis, Meir ^a   Weisz, Anat ^a   Koren, Belly ^a   Lewis, Basil S ^a   Flugelman, Moshe Y ^a  

^a CARMEL MEDICAL CENTER   (Israel)

Author keywords

Adenoviral vectors; Angiogenesis; Postangioplasty restenosis; Retroviral vectors

Indexed keywords

ADENOVIRUS VECTOR; CARDIOVASCULAR AGENT; CYCLOOXYGENASE 1; HIRUDIN; MATRIX METALLOPROTEINASE INHIBITOR; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; RETROVIRUS VECTOR; THYMIDINE KINASE; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; VIRUS VECTOR;

ANGIOGENESIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS SURGERY; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; IN VIVO STUDY; MEDICAL RESEARCH; NONHUMAN; RESTENOSIS; VIRAL GENE DELIVERY SYSTEM;

EID: 0036768120     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (61)

1. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992;1:363-9.
2. Felgner PL. Improvement in cationic liposomes for in vivo gene transfer. Hum Gene Ther 1996,7:1791-3.
3. Yla-Herttuala S. Vascular gene transfer. Curr Opin Lipidol 1997;8:72-6.
4. Harvey BG, Hackett NR, El-Sawy T, et al. Variability of human systemic immune response to adenovirus gene transfer vectors administered to different organs. J Virol 1999;73:6729-42.
5. Mastrangeli A, Harvey BG, Yao J, et al. Sero-switch adenovirus mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenoviral vector administration by changing the adenoviral sertotype. Hum Gene Ther 1996;7:79-87.
6. Wen S, Driscoll RM, Schneider DB, Dichek DA. Inclusion of the E3 region in an adenoviral vector decreases inflammation and neointima formation after arterial gene transfer. Arterioscler Thromb Vasc Biol 2001;21:1777-82.
7. Themis M, Forbes SJ, Chan L, et al. Enhanced in vitro and in vivo gene delivery using cationic agent complexed retrovirus vectors. Gene Ther 1998;5:1180-6.
8. Kahn ML, Lee SW, Dichek DA. Optimization of retroviral vector-mediated gene transfer into endothelial cells in vitro. Circ Res 1992;71:1508-17.
9. Sinnayah P, Lindley TE, Staber PD, Cassell MD, Davidson BL, Davisson RL. Selective gene transfer to key cardiovascular regions of the brain: Comparison of two viral vector systems. Hypertension 2002;39:603-8.
10. Kuhn U, Terunuma A, Pfutzner W, Foster RA, Vogel JC. In vivo assessment of gene delivery to keratinocytes by lentiviral vectors. J Virol 2002;76:1496-504.
11. Wickham TJ, Segal DM, Roelvink PW, et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996;70:6831-8.
12. Bestor TH. Gene silencing as a threat to the success of gene therapy. J Clin Invest 2000;105:409-11.
13. Vile RG, Russell SJ. Retroviruses as vectors. Br Med Bull 1995;51:12-30.
14. Kiem HP, McSweeney PA, Bruno B, et al. Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus pseudotype retroviral vector. Gene Ther 1999;6:966-72.
15. Miller AD, Miller DG, Garcia JV, Lynch CM. Use of retroviral vectors for gene transfer and expression. Methods Enzymol 1993;217:581-99.
16. Fallaux FJ, Van Der Eb AJ, Hoeben RC. Who is afraid of replication-competent adenoviruses? Gene Ther 1999;9:709-12.
17. Spergel LM, Chen-Kiang S. Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation. Proc Natl Acad Sci USA 1991;88:6472-6.
18. Harvey BG, Maroni J, O'Donoghue KA, et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther 2002;13:15-63.
19. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-93.
20. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
21. Rome JJ, Shayani V, Flugelman MY, et al. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Arterioscler Thromb 1994;14:148-61.
22. Lewis BS, Flugelman MY, Weisz A, Keren-Tal I, Schaper W. Angiogenesis by gene therapy: A new horizon for myocardial revascularization? Cardiovasc Res 1997;35:490-7.
23. Flugelman MY, Virmani R, Leon MB, Bowman RL, Dichek DA. Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to flow in vitro. Circ Res 1992;70:348-54.
24. Kremer EJ, Perricaudet M. Adenovirus and adeno-associated virus mediated gene transfer. Br Med Bull 1995;51:31-44.
25. Smaglik P. After gene therapy death investigators ponder what went wrong. Scientist 1999;13:21.
26. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999;401:517-8.
27. Hollon T. Researchers and regulators reflect on first gene therapy death. Nat Med 2000;6:6.
28. Levy JA, Owens RA, Frankel-Corat H, eds. Virology, 3rd edn. Upper Saddle River: Prenticer-Hall, 1994:129-33, 189-90.
29. Parks RJ, Graham FL. A helper dependent system for adenoviral vector production helps define a lower limit for efficient DNA packaging. J Virol 1997;71:3293-8.
30. Christ M, Lusky M, Stoeckel F, et al. Gene therapy with recombinant adenoviral vectors: Evaluation of the host immune response. Immunol Lett 1997;57:19-25.
31. Morral N, O'Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 1999;96:12816-21.
32. Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of preexisting and induced humoral and cellular immune response in an adenoviral based gene transfer phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998;9:2121-33.
33. Cassivi SD, Liu M, Boehler A, et al. Transgene expression after adenovirus-mediated retransfection of rat lungs is increased and prolonged by transplant immunosuppression. J Thorac Cardiovasc Surg 1999;117:1-7.
34. Ilan Y, Sauter B, Chowdhury NR, et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998;27:1368-76.
35. Harari OA, Wickham TJ, Stocker CJ, et al. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Ther 1999;6:801-7.
36. Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg 1999;230:466-70.
37. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001;104:753-5.
38. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-74.
39. Yee JK, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedmann TA. A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994;91:9564-8.
40. Forestell SP, Dando JS, Chen J, De Vries P, Bohnlein E, Rigg RJ. Novel retroviral packaging cell lines: Complementary tropisms and improved vector production for efficient gene transfer. Gene Ther 1997;4:600-10.
41. Scott-Taylor TH, Gansbacher B, Sadelain M. Efficient retroviral infection of human cells utilising an adenoviral vector expressing the ecotropic receptor. Adv Exp Med Biol 1998;451:423-30.
42. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995;1:1148-54.
43. Amado RG, Chen ISY. Lentiviral vectors - The promise of gene therapy within reach? Science 1999;285:674-6.
44. Sakoda T, Kasahara N, Hamamori Y, Kedes L. A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J Mol Cell Cardiol 1999;31:2037-47.
45. Kotin RM, Linden RM, Berns KI. Characterization of a preferred site on chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 1992;11:5071-8.
46. Rolling F, Shen WY, Tabarias H, et al. Evaluation of adeno-associated virus-mediated gene transfer into the rat retina by clinical fluorescence photography. Hum Gene Ther 1999;10:641-8.
47. Herzog RW, Hagstrom JN, Kung SH, et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997;94:5804-9.
48. Shimpo M, Ikeda U, Maeda Y, et al. AAV-mediated VEGF gene transfer into skeletal muscle stimulates angiogenesis and improves blood flow in a rat hindlimb ischemia model. Cardiovasc Res 2002;53:993-1001.
49. Jung SC, Han IP, Limaye A, et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs in Fabry mice. Proc Natl Acad Sci USA 2001;98:2676-81.
50. Su H, Lu R, Kan YW. Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc Natl Acad Sci USA 2000;97:13801-6.
51. Lundstrom K, Schweitzer C, Rotmann D, Hermann D, Schneider EM, Ehrengruber MU. Semliki forest virus vectors: Efficient vehicles for in vitro and in vivo gene delivery. FEBS Lett 2001;504:99-103.
52. Roks AJ, Henning RH, Buikema H, et al. Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta. Gene Ther 2002;9:95-101.
53. Bittl JA. Advances in coronary angioplasty. N Engl J Med 1996;335:1290-302.
54. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenovirus-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nat Med 1996;2:293-8.
55. Waugh JM, Kattash M, Li J, et al. Gene therapy to promote thromboresistance: Local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA 1999;96:1065-70.
56. Zoldhelyi P, McNatt J, Xu XM, et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation 1996;93:10-7.
57. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo supression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 1994;91:10732-6.
58. Mack CA, Magovern CJ, Budenbender KT, et al. Salvage angiogenesis induced by adenovirus-mediated gene transfer of vascular endothelial growth factor protects against ischemic vascular occlusion. J Vasc Surg 1998;27:699-799.
59. Seguret-Mace S, Latta-Mahieu M, Castro G, et al. Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 1996;94:2177-84.
60. Cheng L, Mantile G, Pauly R, et al. Adenovirus-mediated gene transfer of human TIMP-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 1998;98:2195-201.
61. Lin KF, Chao L, Chao J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 1997;30:307-13.